Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'salvage chemotherapy' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 164 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Jelic, S; Babovic, N; Stamatovic, L; Kreacic, M; Matkovic, S; Popov, I
      Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study

      MEDICAL ONCOLOGY
    2. Hurwitz, CA; Strauss, LC; Kepner, J; Kretschmar, C; Harris, MB; Friedman, H; Kun, L; Kadota, R
      Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study

      JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
    3. Jagodic, M; Cufer, T; Zakotnik, B; Cervek, J
      Selection of candidates for oral etoposide salvage chemotherapy in heavilypretreated breast cancer patients

      ANTI-CANCER DRUGS
    4. Perea, G; Sureda, A; Martino, R; Altes, A; Martinez, C; Cabezudo, E; Amill, B; Martin-Henao, GA; Gonzalez, Y; Munoz, L; Peyret, M; Brunet, S; Sierra, J
      Predictive factors for a successful mobilization of peripheral blood CD34(+) cells in multiple myeloma

      ANNALS OF HEMATOLOGY
    5. Pectasides, D; Aravantinos, G; Kalofonos, H; Kiamouris, C; Bafaloukos, D; Xiros, N; Nicolaides, C; Visvikis, A; Dimopoulos, MA
      Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group

      ANNALS OF ONCOLOGY
    6. Reiser, M; Bredenfeld, H; Engert, A; Diehl, V
      The role of ifosfamide in the treatment of relapsed and refractory lymphoma

      EUROPEAN JOURNAL OF HAEMATOLOGY
    7. Coleman, M; Leonard, J; Shuster, MW; Kaufman, TP
      DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL)

      EUROPEAN JOURNAL OF HAEMATOLOGY
    8. Kobrinsky, NL; Sposto, R; Shah, NR; Anderson, JR; DeLaat, C; Morse, M; Warkentin, P; Gilchrist, GS; Cohen, MD; Shina, D; Meadows, AT
      Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group study CCG-5912

      JOURNAL OF CLINICAL ONCOLOGY
    9. Chinot, OL; Honore, S; Dufour, H; Barrie, M; Figarella-Branger, D; Muracciole, X; Braguer, D; Martin, PM; Grisoli, F
      Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy

      JOURNAL OF CLINICAL ONCOLOGY
    10. Hartmann, JT; Einhorn, L; Nichols, CR; Droz, JP; Horwich, A; Gerl, A; Fossa, SD; Beyer, J; Pont, J; Schmoll, HJ; Kanz, L; Bokemeyer, C
      Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: Results of an international multicenter analysis

      JOURNAL OF CLINICAL ONCOLOGY
    11. Lee, ST; Jang, JH; Suh, HC; Hahn, JS; Ko, YW; Min, YH
      Idarubicin, cytarabine, and topotecan in patients with refractory or relapsed acute myelogenous leukemia and high-risk myelodysplastic syndrome

      AMERICAN JOURNAL OF HEMATOLOGY
    12. Rick, O; Siegert, W; Beyer, J
      Chemotherapy in patients with metastatic or relapsed germ-cell tumours

      CANCER TREATMENT REVIEWS
    13. Hanna, N; Gharpure, VS; Abonour, R; Cornetta, K; Loehrer, PJ
      High-dose carboplatin with etoposide in patients with recurrent thymoma: the Indiana University experience

      BONE MARROW TRANSPLANTATION
    14. Magagnoli, M; Sarina, B; Balzarotti, M; Castagna, L; Timofeeva, I; Nozza, A; Bertuzzi, A; Siracusano, L; Sinnone, M; Santoro, A
      Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma

      BONE MARROW TRANSPLANTATION
    15. van Besien, K; Rodriguez, A; Tomany, S; Younes, A; Donate, M; Sarris, A; Giralt, S; Mehra, R; Andersson, B; Gajewski, J; Champlin, R; Cabanillas, F
      Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

      BONE MARROW TRANSPLANTATION
    16. Pectasides, D; Kalofonos, HP; Samantas, E; Nicolaides, C; Papacostas, P; Onyenadum, A; Visvikis, A; Skarlos, D; Fountzilas, G
      An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group

      ANTICANCER RESEARCH
    17. Chinot, O
      Chemotherapy for the treatment of oligodendroglial tumors

      SEMINARS IN ONCOLOGY
    18. Orlando, M; Mandachain, M
      Gemcitabine in ovarian cancer

      SEMINARS IN ONCOLOGY
    19. Comella, P; Biglietto, M; Casaretti, R; De Luica, L; Avallone, A; Maiorino, L; Di Lullo, L; De Cataldis, G; Rivellini, F; Comella, G
      Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients - A phase I/II study of the Southern Italy Cooperative Oncology Group

      ONCOLOGY
    20. van den Bent, MJ; Keime-Guibert, F; Brandes, AA; Taphoorn, MJB; Kros, JM; Eskens, FALM; Carpentier, AF
      Temozolomide chemotherapy in recurrent oligodendroglioma

      NEUROLOGY
    21. Villela, L; Lopez-Guillermo, A; Montoto, S; Rives, S; Bosch, F; Perales, M; Ferrer, A; Esteve, J; Colomo, L; Campo, E; Montserrat, E
      Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens

      CANCER
    22. Kancherla, RR; Nair, JS; Ahmed, T; Durrani, H; Seiter, K; Mannancheril, A; Tse-Dinh, YC
      Evaluation of topotecan and etoposide for non-Hodgkin lymphoma - Correlation of topoisomerase-DNA complex formation with clinical response

      CANCER
    23. Chang, SM; Kuhn, JG; Robins, HI; Schold, SC; Spence, AM; Berger, MS; Mehta, MP; Pollack, IF; Rankin, C; Prados, MD
      A phase II study of paclitaxel in patients with recurrent malignant gliomausing different doses depending upon the concomitant use of anticonvulsants - A North American Brain Tumor Consortium report

      CANCER
    24. Chen, CI; Crump, M; Tsang, R; Stewart, AK; Keating, A
      Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma

      BRITISH JOURNAL OF HAEMATOLOGY
    25. Kalbakis, K; Kouroussis, C; Kakolyris, S; Mavroudis, D; Souglakos, J; Agelaki, S; Vamvakas, L; Christodoulakis, M; Stylianou, K; Georgoulias, V
      Salvage chemotherapy with high-dose leucovorin (LV) and 48-hour continuousinfusion (CI) of 5-fluorouracil (5-FU) in combination with conventional doses of cyclophosphamide (CPM) in patients with metastatic breast cancer (MBC) pretreated with anthracycline and taxanes

      BRITISH JOURNAL OF CANCER
    26. Bensmaine, MA; Marty, M; de Gramont, A; Brienza, S; Levi, F; Ducreux, M; Francois, E; Gamelin, E; Bleiberg, H; Cvitkovic, E
      Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

      BRITISH JOURNAL OF CANCER
    27. Cairncross, G; Swinnen, L; Bayer, R; Rosenfeld, S; Salzman, D; Paleologos, N; Kaminer, L; Forsyth, P; Stewart, D; Peterson, K; Hu, W; Macdonald, D; Ramsay, D; Smith, A
      Myeloablative chemotherapy for recurrent aggressive oligodendroglioma

      NEURO-ONCOLOGY
    28. Walewski, J; Krzyzanowska, JB; Kraszewska, E; Lampka, E; Romejko-Jarosinska, J; Miskiewicz, Z; Meder, J
      CN3OP: an active regimen in patients with relapsed/refractory Hodgkin's lymphoma

      MEDICAL ONCOLOGY
    29. Ferra, C; Berlanga, JJ; Gallardo, D; Ancin, I; Marin, D; Gonzalez, JR; Peris, J; Munoz, J; Sarra, J; Granena, A
      Mitoxantrone, etoposide, carboplatinum and ara-C combination therapy (Meca) in refractory and relapsed acute leukemia

      LEUKEMIA & LYMPHOMA
    30. Itoh, K; Ohtsu, T; Sasaki, Y; Ogura, M; Morishima, Y; Kasai, M; Chou, T; Yoshida, K; Ohno, T; Mizorogi, F; Uike, N; Sai, T; Taniwaki, M; Ikeda, S; Tobinai, K
      Randomized comparison of mobilization kinetics of circulating CD34+cells between biweekly CHOP and dose-escalated CHOP with the prophylactic use of lenograstim (glycosylated rHuG-CSF) in aggressive non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    31. Child, JA; Johnson, SA; Rule, S; Smith, GM; Morgan, GJ; Johnson, PWM; Prentice, AG; Tollerfield, SM; Wareham, E
      FLUDAP: Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma

      LEUKEMIA & LYMPHOMA
    32. Sato, K; Tsuchiya, S; Minato, K; Sunaga, N; Ishihara, SI; Makimoto, T; Naruse, I; Hoshino, H; Watanabe, S; Saitoh, R; Mori, M
      Weekly CODE chemotherapy with recombinant human granulocyte colony-stimulating factor for relapsed or refractory small cell lung cancer

      ONCOLOGY REPORTS
    33. Bensmaine, MA; de Gramont, A; Brienza, S; Marty, M; Levi, F; Ducreux, M; Francois, E; Gamelin, E; Bleiberg, H; Bleuzen, P; Simon, J; Cvitkovic, E
      Factors predicting for efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU)+/- folinic acid (FA) in a compassionate-use cohort of 370 5-FU-resistant advanced colorectal cancer (CRC) patients

      EUROPEAN JOURNAL OF CANCER
    34. Postma, TJ; Heimans, JJ; Luykx, SA; van Groeningen, CJ; Beenen, LFM; Hoekstra, OS; Taphoorn, MJB; Zonnenberg, BA; Klein, M; Vermorken, JB
      A phase II study of paclitaxel in chemonaive patients with recurrent high-grade glioma

      ANNALS OF ONCOLOGY
    35. Saotome, T; Takagi, T; Sakai, C; Kumagai, K; Tamaru, J
      Combination chemotherapy with irinotecan and adriamycin for refractory andrelapsed non-Hodgkin's lymphoma

      ANNALS OF ONCOLOGY
    36. Conte, PF; Cianci, C; Tanganelli, L; Gadducci, A
      Ovarian cancer: optimal chemotherapy in relapsed disease

      ANNALS OF ONCOLOGY
    37. Srinivas, S
      High-dose chemotherapy in poor-risk germ-cell tumors

      ONCOLOGY-NEW YORK
    38. Nardi, M; De Marco, S; Fabi, A; Aloe, A; Magnani, E; Grandinetti, P; Cognetti, F
      Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    39. Streffer, J; Schabet, M; Bamberg, M; Grote, EH; Meyermann, R; Voigt, K; Dichgans, J; Weller, M
      A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors

      JOURNAL OF NEUROLOGY
    40. Nieder, C; Grosu, AL; Molls, M
      A comparison of treatment results for recurrent malignant gliomas

      CANCER TREATMENT REVIEWS
    41. Vantelon, JM; Koscielny, S; Brault, P; Bourhis, JH; Ribrag, V; Pico, J; Fenaux, P; Munck, JN
      Scoring system for the prediction of successful peripheral blood stem cell(PBSC) collection in non-Hodgkin's lymphoma (NHL): application in clinicalpractice

      BONE MARROW TRANSPLANTATION
    42. Hartmann, JT; Kanz, L; Bokemeyer, C
      Phase II study of continuous 120-hour- infusion of mitomycin C as salvage chemotherapy in patients with progressive or rapidly recurrent gastrointestinal adenocarcinoma

      ANTICANCER RESEARCH
    43. Chen, YM; Perng, RP; Yang, KY; Lin, WC; Wu, HW; Tsai, CM; Whang-Peng, J
      Phase II study of tamoxifen, ifosfamide, epirubicin and cisplatin combination chemotherapy in patients with non-small cell lung cancer failing previous chemotherapy

      LUNG CANCER
    44. Sculier, JP; Lafitte, JJ; Berghmans, T; Thiriaux, J; Lecomte, J; Efremidis, A; Ninane, V; Paesmans, M; Mommen, P; Klastersky, J
      A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer

      LUNG CANCER
    45. Venturino, A; Comandini, D; Simoni, C; Merlini, L; Naso, C; Palumbo, R; Fusco, V; Porcile, G; Pronzato, P; Rosso, R; Repetto, L
      Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? A phase II randomized trial of vinorelbine versus 5-fluorouracil plus leucovorin versus combination of mitoxantrone, 5-fluorouracil plus leucovorin

      BREAST CANCER RESEARCH AND TREATMENT
    46. Sanson, M; Napolitano, M; Yaya, R; Keime-Guibert, F; Broet, P; Hoang-Xuan, K; Delattre, JY
      Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study

      JOURNAL OF NEURO-ONCOLOGY
    47. Zanotti, KM; Belinson, JL; Kennedy, AW; Webster, KD; Markman, M
      Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy

      GYNECOLOGIC ONCOLOGY
    48. Irie, T; Kigawa, J; Minagawa, Y; Oishi, T; Takahashi, M; Shimada, M; Kamazawa, S; Sato, S; Terakawa, N
      Alteration of a p53 gene status affects outcome of patients with recurrentovarian cancer

      ONCOLOGY
    49. Kewalramani, T; Zelenetz, AD; Hedrick, EE; Donnelly, GB; Hunte, S; Priovolos, AC; Qin, J; Lyons, NC; Yahalom, J; Nimer, SD; Moskowitz, CH
      High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis

      BLOOD
    50. Buzzi, M; Granchi, D; Bacci, G; Ferrari, S; Fogli, M; Fiori, F; Tarabusi, C; Venezian, T; Pederzoli, A; Pizzoferrato, A
      Cd34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma

      JOURNAL OF CHEMOTHERAPY
    51. Glantz, MJ; Chamberlain, MC; Chang, SM; Prados, MD; Cole, BF
      The role of paclitaxel in the treatment of primary and metastatic brain tumors

      SEMINARS IN RADIATION ONCOLOGY
    52. McBride, NC; Ward, MC; Mills, MJ; Eden, AG; Hughes, A; Cavenagh, JD; Lamont, A; Newland, AC; Kelsey, SM
      Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation

      LEUKEMIA & LYMPHOMA
    53. Petit, J; Boque, C; Cancelas, JA; Sarra, J; Munoz, J; Garcia, J; Granena, A
      Feasibility of ESHAP plus G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients

      LEUKEMIA & LYMPHOMA
    54. Soussain, C; Souleau, B; Gabarre, J; Zouabi, H; Sutton, L; Boccaccio, C; Albin, N; Charlotte, F; Merle-Beral, H; Delort, J; Binet, JL; Leblond, V
      Intensive chemotherapy with hematopoietic cell transplantation after ESHAPtherapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients

      LEUKEMIA & LYMPHOMA
    55. Zinzani, PL; Magagnoli, M; Frezza, G; Barbieri, E; Gherlinzoni, F; Galuppi, A; Bendandi, M; Merla, E; Albertini, P; Tura, S
      ABVD and radiation therapy as first-line treatment in advanced Hodgkin's disease

      LEUKEMIA & LYMPHOMA
    56. Rha, SY; Chung, HC; Gong, SJ; Shim, KY; Ahn, JB; Yang, WI; Shin, KH; Yoo, NC; Kim, JH; Roh, JK; Lee, CI; Kim, BS
      Combined pre-operative chemotherapy with intra-arterial cisplatin and continuous intravenous adriamycin for high grade osteosarcoma

      ONCOLOGY REPORTS
    57. Hara, I; Yamada, Y; Miyake, H; Nomi, M; Hara, S; Yamanaka, K; Takechi, Y; Oka, Y; Nakamura, I; Gotoh, A; Gohji, K; Arakawa, S; Kamidono, S
      Clinical outcome of high-dose chemotherapy combined with peripheral blood stem cell transplantation for male germ cell tumors

      ANTI-CANCER DRUGS
    58. Hartmann, JT; Quietzsch, D; Daikeler, T; Kollmannsberger, C; Mayer, F; Kanz, L; Bokemeyer, C
      Mitomycin C continuous infusion as salvage chemotherapy in pretreated patients with advanced gastric cancer

      ANTI-CANCER DRUGS
    59. Faivre, S; Kalla, S; Cvitkovic, E; Bourdon, O; Hauteville, D; Dourte, LM; Bensmaine, MA; Itzhaki, M; Marty, M; Extra, JM
      Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

      ANNALS OF ONCOLOGY
    60. Aparicio, J; Segura, A; Garcera, S; Oltra, A; Santaballa, A; Yuste, A; Pastor, M
      ESHAP is an active regimen for relapsing Hodgkin's disease

      ANNALS OF ONCOLOGY
    61. Spielmann, M; Llombart, A; Zelek, L; Sverdlin, R; Rixe, O; Le Cesne, A
      Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer

      ANNALS OF ONCOLOGY
    62. Brienza, S; Bensmaine, MA; Soulie, P; Louvet, C; Gamelin, E; Francois, E; Ducreux, M; Marty, M; Andre, T; de Braud, F; Bleiberg, H; Segal, V; Itzhaki, M; Cvitkovic, E
      Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): Results from the European compassionate-use program

      ANNALS OF ONCOLOGY
    63. Moskowitz, CH; Bertino, JR; Glassman, JR; Hedrick, EE; Hunte, S; Coady-Lyons, N; Agus, DB; Goy, A; Jurcic, J; Noy, A; O'Brien, J; Portlock, CS; Straus, DS; Childs, B; Frank, R; Yahalom, J; Filippa, D; Louie, D; Nimer, SD; Zelenetz, AD
      Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

      JOURNAL OF CLINICAL ONCOLOGY
    64. Andre, M; Henry-Amar, M; Pico, JL; Brice, P; Blaise, D; Kuentz, M; Coiffier, B; Colombat, P; Cahn, JY; Attal, M; Fleury, J; Milpied, N; Nedellec, G; Biron, P; Tilly, H; Jouet, JP; Gisselbrecht, C
      Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study

      JOURNAL OF CLINICAL ONCOLOGY
    65. Martino, R; Bellido, M; Brunet, S; Altes, A; Sureda, A; Guardia, R; Aventin, A; Nomedeu, JF; Domingo-Albos, A; Sierra, J
      Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: results of a prospective trial

      HAEMATOLOGICA
    66. Martino, R; Guardia, R; Altes, A; Sureda, A; Brunet, S; Sierra, J
      Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II GEMIA protocol

      HAEMATOLOGICA
    67. Lopez, R; Martino, R; Brunet, S; Sureda, A; Domingo-Albos, A; Sierra, J
      Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas

      HAEMATOLOGICA
    68. Kohno, N; Kitahara, S; Kawaida, M; Ohmuma, T
      Prognosis after salvage chemotherapy for locally unresectable recurrent squamous cell carcinoma of the head and neck

      JAPANESE JOURNAL OF CLINICAL ONCOLOGY
    69. Shah, AB; Hudson, MM; Poquette, CA; Luo, XL; Wilimas, JA; Kun, LE
      Long-term follow-up of patients treated with primary radiotherapy for supradiaphragmatic Hodgkin's disease at St. Jude Children's Research Hospital

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    70. Silver, DF; Piver, MS
      Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    71. Haim, N; Drumea, K; Epelbaum, R; Ben-Shahar, M
      Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy innon-Hodgkin lymphoma

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    72. Mayer, J; Koristek, Z; Vasova, I; Vorlicek, J; Vodvarka, P
      Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma

      BONE MARROW TRANSPLANTATION
    73. Bauernhofer, T; Stoger, H; Kasparek, AK; Ploner, F; Kuss, I; Pieber, TR; Kotz, R; Samonigg, H
      Combined treatment of metastatic osteosarcoma of the spine

      ONCOLOGY
    74. Morris, MJ; Bosl, GJ
      High-dose chemotherapy as primary treatment for poor-risk germ-cell tumors: The Memorial Sloan-Kettering Experience (1988-1999)

      INTERNATIONAL JOURNAL OF CANCER
    75. Rodriguez, J; Rodriguez, MA; Fayad, L; McLaughlin, P; Swan, F; Sarris, A; Romaguera, J; Andersson, B; Cabanillas, F; Hagemeister, FB
      ASHAP: A regimen for cytoreduction of refractory or recurrent Hodgkin's disease

      BLOOD
    76. HARTMANN JT; HARSTRICK A; DAIKELER T; KOLLMANNSBERGER C; MULLER C; SEEBER S; KANZ L; BOKEMEYER C
      PHASE-II STUDY OF CONTINUOUS 120 H INFUSION OF MITOMYCIN-C AS SALVAGECHEMOTHERAPY IN PATIENTS WITH PROGRESSIVE OR RAPIDLY RECURRENT COLORECTAL-CANCER

      Anti-cancer drugs
    77. Itoh, K; Igarashi, T; Ohtsu, T; Wakita, H; Watanabe, Y; Fujii, H; Minami, H; Sasaki, Y
      Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma

      INTERNATIONAL JOURNAL OF HEMATOLOGY
    78. Canellos, GP
      Treatment of relapsed Hodgkin's disease: Strategies and prognostic factors

      ANNALS OF ONCOLOGY
    79. Horning, SJ
      Primary refractory Hodgkin's disease

      ANNALS OF ONCOLOGY
    80. STIFF PJ
      BLOOD AND MARROW TRANSPLANTATION IN RELAPSED OR REFRACTORY NON-HODGKINS-LYMPHOMA

      Oncology
    81. KITA T; KIKUCHI Y; HIRATA J; NAGATA I
      PROGNOSIS OF OVARIAN CANCERS TODAY

      The Cancer journal
    82. LITTLE R; WITTES RE; LONGO DL; WILSON WH
      VINBLASTINE FOR RECURRENT HODGKINS-DISEASE FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANT

      Journal of clinical oncology
    83. FIZAZI K; CULINE S; DROZ JP; KRAMAR A; THEODORE C; RUFFIE P; LECHEVALIER T
      PRIMARY MEDIASTINAL NONSEMINOMATOUS GERM-CELL TUMORS - RESULTS OF MODERN THERAPY INCLUDING CISPLATIN-BASED CHEMOTHERAPY

      Journal of clinical oncology
    84. STIFF PJ; DAHLBERG S; FORMAN SJ; MCCALL AR; HORNING SJ; NADEMANEE AP; BLUME KG; LEBLANC M; FISHER RI
      AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE AGGRESSIVE NON-HODGKINS-LYMPHOMA - VALUE OF AUGMENTED PREPARATIVE REGIMENS - A SOUTHWEST-ONCOLOGY-GROUP TRIAL

      Journal of clinical oncology
    85. TESCH H; BOHLEN H; WOLF J; ENGERT A
      PATHOGENESIS AND TREATMENT OF HODGKINS-DI SEASE

      Medizinische Klinik
    86. REISER M; BORCHMANN P; DIEHL V; ENGERT A
      IFOSFAMIDE IN THE TREATMENT OF RELAPSED LYMPHOMA

      Onkologie
    87. Weinknecht, S; Hartmann, M; Weissbach, L
      Marker-positive patients with germ-cell tumors: when is residual tumor resection useful?

      UROLOGE-AUSGABE A
    88. KOUROUSIS C; KAKOLYRIS S; ANDROULAKIS N; HERAS P; VLACHONICOLIS J; VAMVAKAS L; VLATA M; HATZIDAKI D; SAMONIS G; GEORGOULIAS V
      SALVAGE CHEMOTHERAPY WITH PACLITAXEL, VINORELBINE, AND CISPLATIN (PVC) IN ANTHRACYCLINE-RESISTANT ADVANCED BREAST-CANCER

      American journal of clinical oncology
    89. Russell, NH; McQuaker, G; Stainer, C; Byrne, JL; Haynes, AP
      Stem cell mobilisation in lymphoproliferative diseases

      BONE MARROW TRANSPLANTATION
    90. SCHMOLL HJ; BEYER J
      PROGNOSTIC FACTORS IN METASTATIC GERM-CELL TUMORS

      Seminars in oncology
    91. TONER GC; MOTZER RJ
      POOR-PROGNOSIS GERM-CELL TUMORS - CURRENT STATUS AND FUTURE-DIRECTIONS

      Seminars in oncology
    92. OSIEKA R
      PALLIATIVE CANCER-CHEMOTHERAPY

      Zentralblatt fur Chirurgie
    93. HASENCLEVER D; DIEHL V
      A PROGNOSTIC SCORE FOR ADVANCED HODGKINS-DISEASE

      The New England journal of medicine
    94. VANDENBENT MJ; KROS JM; HEIMANS JJ; PRONK LC; VANGROENINGEN CJ; KROUWER HGJ; TAPHOORN MJB; ZONNENBERG BA; TIJSSEN CC; TWIJNSTRA A; PUNT CJA; BOOGERD W
      RESPONSE RATE AND PROGNOSTIC FACTORS OF RECURRENT OLIGODENDROGLIOMA TREATED WITH PROCARBAZINE, CCNU, AND VINCRISTINE CHEMOTHERAPY

      Neurology
    95. GOBBI PG; PIERESCA C; GHIRARDELLI ML; DIRENZO N; FEDERICO M; MERIL F; IANNITTO E; PITINI V; GRIGNANI G; DONELLI A; CAROTENUTO M; SILINGARDI V
      LONG-TERM RESULTS FROM MOPPEBVCAD CHEMOTHERAPY WITH OPTIONAL LIMITED RADIOTHERAPY IN ADVANCED HODGKINS-DISEASE

      Blood
    96. BRADER KR; WOLF JK; HUNG MC; YU DH; CRISPENS MA; VANGOLEN KL; PRICE JE
      ADENOVIRUS E1A EXPRESSION ENHANCES THE SENSITIVITY OF AN OVARIAN-CANCER CELL-LINE TO MULTIPLE CYTOTOXIC AGENTS THROUGH AN APOPTOTIC MECHANISM

      Clinical cancer research
    97. LINASMITA V; WILAILAK S; SRISUPUNDIT S; TANGTRAKUL S; BULLANGPOTI S; ISRANGURA N
      IFOSFAMIDE MESNA PLUS ADRIAMYCIN AS SALVAGE THERAPY OF ADVANCED EPITHELIAL OVARIAN-CANCER/

      International journal of gynecological cancer
    98. PHILLIPS GL; REECE DE; WOLFF SN; GOLDIE JH
      THE USE OF CONVENTIONAL SALVAGE CHEMOTHERAPY BEFORE DOSE-INTENSIVE CYTOTOXIC THERAPY AND AUTOLOGOUS TRANSPLANTATION FOR AGGRESSIVE-HISTOLOGY LYMPHOMA - A CASE FOR REEVALUATION

      Leukemia & lymphoma
    99. DAVIDGEPITTS M; DANSEY R; BEZWODA WR
      SALVAGE TREATMENT AFTER FAILURE OR RELAPSE FOLLOWING INITIAL CHEMOTHERAPY FOR FOLLICULAR NON-HODGKINS-LYMPHOMA

      Leukemia & lymphoma
    100. PINKERTON CR
      MALIGNANT GERM-CELL TUMORS IN CHILDHOOD

      European journal of cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/08/20 alle ore 04:09:18